In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response
-
Published:2022-09-09
Issue:1
Volume:13
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Sahu AditiORCID, Kose KivancORCID, Kraehenbuehl LukasORCID, Byers CandiceORCID, Holland Aliya, Tembo Teguru, Santella Anthony, Alfonso Anabel, Li MadisonORCID, Cordova Miguel, Gill Melissa, Fox Christi, Gonzalez Salvador, Kumar PiyushORCID, Wang Amber Weiching, Kurtansky NicholasORCID, Chandrani PratikORCID, Yin Shen, Mehta Paras, Navarrete-Dechent Cristian, Peterson Gary, King Kimeil, Dusza StephenORCID, Yang NingORCID, Liu Shuaitong, Phillips William, Guitera Pascale, Rossi Anthony, Halpern Allan, Deng LiangORCID, Pulitzer Melissa, Marghoob Ashfaq, Chen Chih-Shan Jason, Merghoub TahaORCID, Rajadhyaksha MilindORCID
Abstract
AbstractResponse to immunotherapies can be variable and unpredictable. Pathology-based phenotyping of tumors into ‘hot’ and ‘cold’ is static, relying solely on T-cell infiltration in single-time single-site biopsies, resulting in suboptimal treatment response prediction. Dynamic vascular events (tumor angiogenesis, leukocyte trafficking) within tumor immune microenvironment (TiME) also influence anti-tumor immunity and treatment response. Here, we report dynamic cellular-level TiME phenotyping in vivo that combines inflammation profiles with vascular features through non-invasive reflectance confocal microscopic imaging. In skin cancer patients, we demonstrate three main TiME phenotypes that correlate with gene and protein expression, and response to toll-like receptor agonist immune-therapy. Notably, phenotypes with high inflammation associate with immunostimulatory signatures and those with high vasculature with angiogenic and endothelial anergy signatures. Moreover, phenotypes with high inflammation and low vasculature demonstrate the best treatment response. This non-invasive in vivo phenotyping approach integrating dynamic vasculature with inflammation serves as a reliable predictor of response to topical immune-therapy in patients.
Funder
Melanoma Research Alliance Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung Harold Alfond Foundation The Chan-Zuckerberg Initiative U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering U.S. Department of Health & Human Services | NIH | National Cancer Institute
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Reference95 articles.
1. Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 27, 450–461 (2015). 2. Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345–1356 (2017). 3. Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018). 4. Darvin, P., Toor, S. M., Nair, V. S. & Elkord, E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp. Mol. Med. 50, 1–11 (2018). 5. Friedman, C. F. & Postow, M. A. Emerging tissue and blood-based biomarkers that may predict response to immune checkpoint inhibition. Curr. Oncol. Rep. 18, 21 (2016).
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|